Qx Therapeutics

What Qx Therapeutics does

Qx Therapeutics Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2017 as a Yale University spinout, headquartered in West Haven, Connecticut. The company is developing a single lead asset, QXT-101, a first-in-class small-molecule inhibitor of the MAP3K2/3 kinase pathway that was discovered in Dr. Dianqing (Dan) Wu's laboratory at Yale and is exclusively licensed from the university. QXT-101 is being advanced for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS), with active Phase 2 programs targeting hospitalized patients with severe COVID-19 lung injury and lung transplant recipients suffering from Primary Graft Dysfunction (PGD), the latter having received FDA Fast-Track Designation in July 2022.

The underlying mechanism reduces alveolar-capillary permeability and interstitial edema through MAP3K2/3 inhibition, and the company reports significantly improved survival in animal proof-of-concept models across multiple ALI/ARDS etiologies including viral infection and ischemia-reperfusion injury. There are currently no FDA-approved pharmacological interventions for ALI/ARDS, an indication with mortality up to 40% and an estimated global market of at least $6 billion by 2021 with 200,000 new U.S. cases annually.

The company is pre-revenue and monetizes through future pharmaceutical commercialization rather than current sales; revenue mechanics will activate post-FDA approval via standard pharmaceutical channels and enterprise sales into hospital systems. Current operating funding consists of a single SBIR Phase 1 grant of $269,641 from the NIH National Heart, Lung, and Blood Institute awarded in September 2019, with a 1–10 person team led by CEO Dr. Xiaofeng Li, COO Dr. Ho Yin Lo, and CFO Stanley Choy. The company maintains a corporate website and communicates primarily through regulatory milestone press releases rather than active marketing.

Name

Qx Therapeutics

Legal name

Qx Therapeutics, Inc.

Website

https://qxtherapeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Qx Therapeutics is a clinical-stage biopharmaceutical company developing QXT-101, a first-in-class MAP3K2/3 inhibitor for Acute Lung Injury, ARDS, COVID-19 lung injury, and Primary Graft Dysfunction in lung transplant recipients.

Ownership category

akta.pro rank

Headquarters

HQ city

Branford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Qx Therapeutics is a privately held pharmaceutical company in clinical development stage. The company is developing QXT-101 through Phase 2 clinical trials for treatment of Acute Lung Injury, COVID-19, and Primary Graft Dysfunction. Revenue will be generated through pharmaceutical product sales following FDA approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Qx Therapeutics is a clinical-stage biopharmaceutical company developing QXT-101, a first-in-class MAP3K2/3 inhibitor for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The lead compound targets MAP3K2/3 to reduce lung permeability and interstitial edema, and is being advanced through Phase 2 clinical trials for severe COVID-19 lung injury and Primary Graft Dysfunction (PGD) in lung transplant recipients.

Product overview

Qx Therapeutics is a drug research and development company with a single lead product candidate, QXT-101. This MAP3K2/3 inhibitor is being developed as a first-in-class treatment for Acute Lung Injury (ALI) and related conditions including ARDS, with clinical programs targeting Pulmonary Graft Dysfunction (PGD) in lung transplant recipients and severe COVID-19 patients.

Differentiator

Problem solved

Functional benefit

Products and services

• QXT-101 QXT-101 is a first-in-class MAP3K2/3 inhibitor drug candidate being developed as a treatment for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). It works through inhibition of the MAP3K2/3 pathway to reduce lung permeability and interstitial edema, and is being advanced in Phase 2 clinical trials targeting severe COVID-19 lung injury and Primary Graft Dysfunction (PGD) in lung transplant recipients, with FDA IND clearances and Fast-Track Designation granted.

Quantifiable outcome

• MAP3K2/3 inhibition significantly reduced permeability and interstitial edema in animal ALI models
• +3 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Yale UniversitycoreTechnology or Integration · 1 January 2017Qx Therapeutics has an exclusive license from Yale University on intellectual property pertinent to the composition, know-how, and pre-clinical results generated in Dr. Dianqing (Dan) Wu's laboratory on treatment of ALI/ARDS via inhibition of MAP3K2/3. Qx Therapeutics is a Yale University spinout company founded in 2017. Prof. Wu serves as Co-Founder and head of scientific advisory board.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Mesoblast: Mesoblast is developing remestemcel-L (a cell therapy) for acute respiratory distress syndrome (ARDS), directly overlapping with Qx Therapeutics' lead indication and a similar clinical-stage approach to severe lung inflammation.
• Athersys: Athersys (with partner Healios in Japan) has been advancing MultiStem cell therapy for ARDS, putting it in direct competition with Qx Therapeutics for the same first-in-class-approved-drug opportunity in ALI/ARDS.
• Pliant Therapeutics: Pliant is a clinical-stage biopharmaceutical company focused on serious fibrotic and pulmonary diseases; its integrin-targeting small molecules provide a comparable clinical-stage pulmonary development model.
• FibroGen: FibroGen has clinical programs in pulmonary diseases (notably IPF with pamrevlumab), positioning it as a comparable clinical-stage small-molecule/biologic developer in adjacent respiratory indications.
• BioMarck Pharmaceuticals: BioMarck is a clinical-stage company developing peptide therapeutics for ALI/ARDS, representing a direct small-molecule/peptide peer to Qx Therapeutics in the same disease area.
• Savara Pharmaceuticals: Savara is a clinical-stage respiratory company developing therapies for rare pulmonary diseases (e.g., molgramostim for aPAP and autoimmune pulmonary alveolar proteinosis), a comparable model of a small respiratory biotech pursuing niche lung indications.

Broad incumbents

• Theravance Biopharma: Theravance is a respiratory-focused biopharma with FDA-approved products (e.g., Yupelri) and a clinical pipeline in pulmonary diseases, representing a more established respiratory therapeutic competitor to Qx.
• United Therapeutics: United Therapeutics is a major pulmonary and lung-transplant player (Remodulin/Tyvaso for PAH, and involvement in xenotransplantation) and a natural potential acquirer of Qx's PGD program given its lung transplant franchise.
• Boehringer Ingelheim: Boehringer Ingelheim markets Ofev (nintedanib) for IPF and other respiratory diseases, and is also the former employer of Qx's COO and regulatory advisor. It represents a dominant incumbent in respiratory pharma and a natural strategic partner for Qx.
• Mallinckrodt: Mallinckrodt has a presence in specialty respiratory/critical care (including inhaled nitric oxide and acute care hospital products), positioning it as a broader critical-care competitor or potential partner for Qx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qx Therapeutics